前往化源商城

Developmental Medicine and Child Neurology 2014-10-01

Treatment of arginase deficiency revisited: guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring.

Wajdi Amayreh, Uta Meyer, Anibh M Das

文献索引:Dev. Med. Child Neurol. 56(10) , 1021-4, (2014)

全文:HTML全文

摘要

Hyperargininaemia is a disorder of the last step of the urea cycle. It is an autosomal recessive disease caused by deficiency of liver arginase-1 and usually presents later in childhood with progressive neurological symptoms including marked spasticity. In contrast with other urea cycle disorders, hyperammonaemia is not usually present but can be a feature. A number of guanidine compounds may accumulate in the blood and cerebrospinal fluid of these patients, which could play an important pathophysiological role. Guanidinoacetate is of particular interest as a well-known potent epileptogenic compound in guanidinoacetate methyltransferase deficiency. We found markedly elevated guanidinoacetate levels in a patient with arginase deficiency, which dropped significantly in response to dietary and medical treatment. Measurement of guanidinoacetate and other guanidino compounds may, therefore, be important for therapeutic monitoring in arginase deficiency.© 2014 Mac Keith Press.

相关化合物

结构式 名称/CAS号 全部文献
甘氨酸 结构式 甘氨酸
CAS:56-40-6
L-鸟氨酸盐酸盐 结构式 L-鸟氨酸盐酸盐
CAS:3184-13-2
乙酸胍 结构式 乙酸胍
CAS:352-97-6
甘氨酸盐酸盐 结构式 甘氨酸盐酸盐
CAS:6000-43-7
肌酸 结构式 肌酸
CAS:57-00-1
L-鸟氨酸二盐酸盐 结构式 L-鸟氨酸二盐酸盐
CAS:6211-16-1